Disease Progression in ms

December 5, 2025 updated by: Hüseyin Bektaş

Prediction of Disease Progression Using Machine Learning Based on Clinical Data in People With Multiple Sclerosis

Demographic and clinical data will be obtained from people with MS. Based on this data, the progression of the disease will be predicted with artificial intelligence.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Demographic and clinical data will be obtained from people with MS. Demographic data; age, gender, disease type, disease duration. Clinical data; Frailty, Physical Activity Level, Walking, Balance, Fatigue, Quality of Life. Based on these data, disease progression will be predicted with artificial intelligence and motor learning.

Study Type

Observational

Enrollment (Estimated)

53

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

MS patients coming to Tatvan State Hospital

Description

Inclusion Criteria:

  • Having been diagnosed with MS

Exclusion Criteria:

  • be literate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
intervention group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fragility level
Time Frame: 3 month
The level of frailty will be measured by the Frailty Index.
3 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hüseyin Bektaş

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 15, 2025

Primary Completion (Estimated)

December 20, 2025

Study Completion (Estimated)

March 1, 2026

Study Registration Dates

First Submitted

March 12, 2025

First Submitted That Met QC Criteria

December 5, 2025

First Posted (Actual)

December 18, 2025

Study Record Updates

Last Update Posted (Actual)

December 18, 2025

Last Update Submitted That Met QC Criteria

December 5, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 53513060613

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The results of the study will be announced

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe